Molecular Therapy Oncology: What's in a name?

Timothy P Cripe^{1

2}

Affiliations

¹ MTO Editor-in-Chief, Professor of Pediatrics, The Ohio State University, Columbus, OH, USA.
² Chief, Division of Pediatric Hematology/Oncology/BMT, Nationwide Chidren's Hospital, Columbus, OH, USA.

Editorial

Timothy P Cripe. Mol Ther Oncolytics. 2023.

. 2023 Nov 10:31:100739.

doi: 10.1016/j.omto.2023.100739. eCollection 2023 Dec 19.

Timothy P Cripe^{1

2}

¹ MTO Editor-in-Chief, Professor of Pediatrics, The Ohio State University, Columbus, OH, USA.
² Chief, Division of Pediatric Hematology/Oncology/BMT, Nationwide Chidren's Hospital, Columbus, OH, USA.

No abstract available

References

1. Fong Y. MTO: a new journal for a maturing field. Mol. Ther. Oncolytics. 2014;1 doi: 10.1038/mto.2014.1. - DOI - PMC - PubMed
1. First Oncolytic Viral Therapy for Melanoma. Cancer Discov. 2016;6:6. doi: 10.1158/2159-8290.CD-NB2015-158. - DOI - PubMed
1. Bach P.B., Giralt S.A., Saltz L.B. FDA Approval of Tisagenlecleucel: Promise and Complexities of a $475 000 Cancer Drug. JAMA. 2017;318:1861–1862. doi: 10.1001/jama.2017.15218. - DOI - PubMed
1. Mitra A., Barua A., Huang L., Ganguly S., Feng Q., He B. From bench to bedside: the history and progress of CAR T cell therapy. Front. Immunol. 2023;14 doi: 10.3389/fimmu.2023.1188049. - DOI - PMC - PubMed
1. Zamecnik A. Immunotherapy insights: Oncolytic viruses struggle to find a spot in a crowded field. Pharm. Technol. 2023 https://www.pharmaceutical-technology.com/features/immunotherapy-insight...